A summary in Friday's PCMA SmartBrief included incorrect 2012 revenue figures for Pfizer and Novartis. Pfizer's revenue last year was $58.986 billion. Novartis reported 2012 sales of $56.673 billion. SmartBrief regrets the error.
The FDA approved Novartis' biosimilar of Amgen's Neupogen, but questions about the drug remain, including how Novartis will price it, whether its labeling will boost or detract from sales, and whether the FDA will allow a nonproprietary name for the drug.
The beginning of open enrollment on Oct. 1 is a key date, but the insurance coverage sold on the Affordable Care Act's exchanges does not take effect until Jan. 1, Sarah Kliff writes. The ACA didn't specify an open enrollment period, so HHS chose Oct. 1 to March 31, Kliff writes.
Pfizer, which generated revenue of $58.986 million last year, topped IndustryWeek's 2013 ranking of the world's largest public manufacturers of pharmaceuticals based on revenue. Following closely was Novartis with revenue of $58.748 million. Not counting its consumer goods revenue, Johnson & Johnson would rank third. Other top companies were Roche Holding, Sanofi and Merck & Co.
La Quinta Inns & Suites has unveiled plans to develop properties in Guatemala, Honduras, Nicaragua and Panama through a partnership with Grupo Santos. La Quinta posted a strong performance in 2012, with 7.9% growth in revenue per available room, a 2.6% increase in occupancy and 10% rise in systemwide revenue, to $1.4 billion.